Scientists at St. Jude Children’s Research Hospital have shown in laboratory findings that a combination of drugs suppressing tumor cell development holds promise to treat the disease.

Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could transform treatment for cancer-induced cachexia, a debilitating syndrome characterized by the progressive loss of skeletal muscle mass. 

The team created a new tool that reduces bias and improves cancer diagnosis across populations

Bacteria may be the next frontier in cancer treatment, according to a team led by researchers at Penn State that devised a new approach of creating bacteria-derived mixtures — or cocktails — to help fight bladder cancer. They tested their mixtures of good and bad bacteria on patient tumor samples and in mice, finding that the cocktails significantly boost the immune system’s ability to fight cancer. 

Inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) frequently overlap, forming a unique clinical entity termed PSC-IBD. A new review published in eGastroenterology highlights the complex bidirectional relationship between these conditions, particularly after colectomy and liver transplantation. While colectomy may not halt PSC progression, it influences cancer risk and pouch outcomes. Liver transplantation extends survival but alters IBD activity and malignancy risk. These findings highlight the need for longitudinal studies to guide surveillance, treatment, and surgical decisions.

No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating them with chemotherapy or radiation — which have undesirable side effects — what if we could train our own immune systems to kill the rogue cells? That’s the idea behind mRNA cancer vaccines, which build on science learned from COVID-19 vaccines to address an even larger health concern.